Questo è quello che abbiamo trovato per te
Se dalla fine dell’emergenza si sono contati quasi 8mila morti quello che non è sempre noto è l’impatto economico della mancata vaccinazione
la nuova circolare del ministero della Salute consente anche la doppia iniezione di vaccino: influenza-Covid.
Campagna adattata alla variante JN.1, raccomandata ai fragili
Pubblicato sulla Gazzetta ufficiale il terzo decreto attuativo della legge
Pubblicato sulla Gazzetta ufficiale il terzo decreto attuativo della legge
Lorusso, per la prima volta da 20 anni questa combinazione cambia lo standard di cura
Grazie alla combinazione con una molecola.
Grazie alla combinazione con una molecola.
A small absolute reduction in noncardiovascular-related mortality among semaglutide recipients was attributable partly to fewer COVID-19 deaths.
Ora che ci sono i vaccini per far partire la campagna vaccinale si aspetta la nuova circolare del ministero della Salute attesa a giorni
Introduction
Post-COVID-19 condition (post COVID, also known as long COVID) is a global public health issue estimated to affect over 100 million people. Common symptoms include fatigue, dyspnoea and cognitive dysfunction (‘brain fog’). Over time, these symptoms have an adverse effect on mental health, physical activity and quality of life (QoL). The condition requires innovative and feasible treatment approaches that can be effective and self-managed. Physical activity is essential for good health; however, aerobic exercise or weightlifting may not be suitable for post COVID patients who experience fatigue or breathlessness. The benefits of yoga include improved flexibility, mobility, body strength and balance. It is also shown to reduce symptoms of fatigue and improve breathing efficiency, mental health and QoL. This study protocol describes the rationale and methods for a randomised controlled trial (RCT) of a yoga-based intervention designed for adults with post COVID.
Methods and analysis
A two-group, parallel, RCT with blinded follow-up assessments. Participants will be randomised with a 1:1 allocation to either a 12-week yoga-based intervention or a 12-week health promotion (active comparison) intervention. In total, 88 participants aged 30–65 years will be recruited and randomised. The primary outcome is health-related QoL (36-item Short-Form). Secondary outcomes are dyspnoea, fatigue, sleep quality, cognitive functions, mental fatigue, depression, anxiety, physical activity, demographic data and physical health measures. Data will be analysed as intention-to-treat basis, using linear mixed modelling. All assessments are conducted at Karolinska Institutet in Stockholm, Sweden. The yoga-based intervention will take place at a yoga studio centrally located in Stockholm city.
Ethics and dissemination
The study is approved by the Swedish Ethical Review Authority, reference number 2023/06518-01. All participants must sign written informed consent before enrolment and are free to withdraw from the study at any point. Key results will be available through research articles and seminars.
Trial registration number
German Clinical Trials Register, DRKS00032837.
Così dicono i segnali che arrivano dall’emisfero Sud del mondo dove con il passaggio dell’inverno i virus si sono massicciamente affacciati
Aiom lancia una campagna per sensibilizzare malati e caregiver
Aiom lancia una campagna per sensibilizzare malati e caregiver
New England Journal of Medicine, Volume 391, Issue 10, September 12, 2024.
Objectives
This study aims to describe the incidence, symptom clusters and determinants of post-acute COVID symptoms using data from the COVID RADAR app in the Netherlands.
Design
Prospective cohort.
Setting
General population in the Netherlands from April 2020 to February 2022.
Participants
A total of 1478 COVID RADAR app users, with data spanning 40 days before to 100 days after positive SARS-CoV-2 test.
Outcome measures
Incidence and duration of 10 new symptoms that developed during acute infection, defined as 10 days prior and 10 days after positive test. Clustering of these post-acute COVID symptoms and associations between factors known in the acute phase and 100-day symptom persistence.
Results
The most frequent post-acute symptoms were cough, loss of smell or taste and fatigue. At 100 days postinfection, 86 (8%) participants still experienced symptoms. Three post-acute COVID symptom clusters were identified: non-respiratory (headache and fatigue; 49% of participants with post-acute COVID symptoms); olfactory (15%) and respiratory (8%). Vaccination was associated with a lower risk of post-acute COVID symptoms 100 days after infection, although CIs were wide (OR: 0.5; 95% CI: 0.2 to 1.5), but not with non-respiratory symptoms (OR: 1.0; 95% CI: 0.3 to 4.4). Severe acute disease increased the risk of post-acute COVID symptoms (OR: 1.4; 95% CI: 1.2 to 1.5; per additional acute symptom).
Conclusions
In this cohort of infected community-dwelling app users, 5%–10% experienced post-acute COVID symptoms. The symptoms cluster in several distinct entities, which differ in incidence, patient characteristics and vaccination effects. This suggests multiple mechanisms underlying the development of post-acute COVID symptoms.
